Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             77 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 32 Alarmin IL-33/ST2 pathway as an inductor of T-cell dependent response in acute and early HIV-infected patients Routy, J.-P.
2 S2 p. 19-20
 artikel
2 1 Analysis of intra-patient, full length HIV gagsequences identifies regions of variability Anderson, E.
2 S2 p. 8
 artikel
3 26 A novel assay to evaluate the response of patient-derived virus to latency-reversing agents ex vivo Lu, H.
2 S2 p. 17-18
 artikel
4 33 A novel bispecific immunoadhesin displays enhanced breadth and potency against diverse HIV-1 subtypes in vitro and in humanized mice Wu, X.
2 S2 p. 20
 artikel
5 40 A systems dynamics approach to identifying novel HIV treatments Yang, H.
2 S2 p. 23
 artikel
6 58 Challenges in developing an educational video on HIV cure research Staunton, C.
2 S2 p. 30
 artikel
7 42 Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals Te Silva, L.o.d.o.r.o.
2 S2 p. 24
 artikel
8 28 Dendritic cells programmed by inflammatory mediators can effectively induce both the immunologic ‘kick’ and ‘kill’ of latent HIV-1 Kristoff, J.
2 S2 p. 18
 artikel
9 22 Development of DOUBLE NICKASE CRISPR aganist latently infected human immunodeficency virus (HIV) Ishola, O.A.
2 S2 p. 16
 artikel
10 36 Dose-dependent effects of HDACi on T cell activation and HIV latency reversal Kuang, X.T.
2 S2 p. 21-22
 artikel
11 14 Effect of substances of abuse on HIV DNA decay during antiretroviral therapy started during early HIV infection Chaillon, A.
2 S2 p. 13
 artikel
12 48 Faster restoration of CD4:CD8 ratio during the first 12 weeks of ART initiated at early HIV infection compared with ART initiated at chronic infection in the same patients Pasternak, A.
2 S2 p. 26
 artikel
13 57 HIV cure research: a survey of Australian people living with HIV on perspectives, perceived benefits and willingness to participate in trials Power, J.
2 S2 p. 29-30
 artikel
14 3 HIV-infected patients with exceptional TCD4+ recovery during effective HAART present a distinct T CD4+ differentiation pattern, higher CD31neg naïve cells and a smaller HIV reservoir Leon-Fuentes, L.
2 S2 p. 8-9
 artikel
15 51 HIV patients and caregivers viewpoints towards participation to future HIV cure-related clinical trials – results from the second part of the French ANRS-APSEC survey Protière, C.
2 S2 p. 27
 artikel
16 17 HIV proviral DNA quantification in a cohort of Japanese patients on long-term ART Stanoeva, K.
2 S2 p. 14
 artikel
17 45 HIV-tat fused to the oligomerisation domain of the c4-binding protein is highly immunogenic and controls EcoHIV challenge in mice Tomusange, K.
2 S2 p. 25
 artikel
18 6 HIV virological controllers in an African cohort Moosa, Y.
2 S2 p. 10
 artikel
19 54 How curing HIV could influence stigma: a qualitative analysis of men who have sex with men in Guangzhou, China Wu, F.
2 S2 p. 28
 artikel
20 52 How to keep high-risk early-phase HIV cure and long-term remission studies ethical: classifying candidate solutions Eyal, N.
2 S2 p. 28
 artikel
21 55 ‘I can coexist with HIV’: a qualitative study of perceptions of HIV “cure” among people living with HIV in Guangzhou, China Ma, Q.
2 S2 p. 29
 artikel
22 11 Identification of a new host cell HDAC complex that controls HIV latency through direct binding to the core promoter Wilhelm, E.
2 S2 p. 11-12
 artikel
23 5 Identification of different HIV-controller phenotypes: looking for the right model of functional cure Dominguez-Molina, B.
2 S2 p. 9-10
 artikel
24 8 IFNα activates latent HIV-1 in non-proliferating latently infected T-cells Sluis, R.M.
2 S2 p. 10-11
 artikel
25 47 Immuno-PET/CT imaging reveals differences in virus and CD4+ cell localization in SIV infected rhesus macaques treated with an anti-α4β7 mab Arthos, J.
2 S2 p. 26
 artikel
26 2 Increased interferon-alpha activity may contribute to defects of B cells and antibody production caused by HIV-1 infection Abudulai, L.N.
2 S2 p. 8
 artikel
27 18 Initiation of ART within 24–48 hours of birth following in utero HIV infection: the Ucwaningo Lwabantwana Study Roider, J.
2 S2 p. 15
 artikel
28 59 Interrupting HIV treatment in cure research: scientific and ethical considerations Garner, S.
2 S2 p. 30
 artikel
29 29 In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels, and latent HIV infection Tsai, P.
2 S2 p. 18-19
 artikel
30 15 Is the lung a site of productive HIV infection that persists through ART? Russell, D.
2 S2 p. 13-14
 artikel
31 56 Is there an implementation ethics to HIV cure-related research? Dube, K.
2 S2 p. 29
 artikel
32 46LB A nonhuman primate model of fully MHC-matched allogeneic stem cell transplantation to study HIV reservoir clearance Burwitz, B.
2 S2 p. 25-26
 artikel
33 50LB Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection Kroon, E.
2 S2 p. 27
 artikel
34 9LB HIV-1 disrupts mitochondrial dynamics: induces fission and mitophagy to attenuate apoptosis in astrocyte Ojeda, D.S.
2 S2 p. 11
 artikel
35 30LB Maraviroc administration is associated to reversion of latent HIV-1 through NFkB in ART suppressed patients Madrid-Elena, N.
2 S2 p. 19
 artikel
36 16LB Whole-body SPECT in Vivo Imaging reveals delayed reconstitution of lymph-nodes, but not spleen, CD4 pools in long-term cART treated animals Di Mascio, M.
2 S2 p. 14
 artikel
37 13 Memory CD4+ T cells expressing HLA-DR contribute to HIV persistence during prolonged ART Lee, E.
2 S2 p. 13
 artikel
38 39 Novel activators and suppressors of latent HIV-1 from natural products Tietjen, I.
2 S2 p. 22-23
 artikel
39 34 Novel conserved element HIV/SIV DNA vaccines maximize breadth and magnitude of immune response Felber, B.K.
2 S2 p. 20
 artikel
40 37 Novel pathways of Tat expression identify new targets for reactivation of latent HIV-1 Lee, M.
2 S2 p. 22
 artikel
41 OA3-1 Allogeneic stem cell transplantation in HIV-1-infected individuals; the EPISTEM consortium Wensing, A.M.
2 S2 p. 4
 artikel
42 OA2-3 BCL-2 antagonism decreases HIV replication and infected cell survival in acute in vitro infection. Cummins, N.
2 S2 p. 2-3
 artikel
43 OA3-2 CCR5 gene edited cells traffic to viral reservoir tissues and undergo SHIV-dependent positive selection in nonhuman primates Peterson, C.W.
2 S2 p. 4
 artikel
44 OA2-2 Cell-associated HIV-1 unspliced RNA level predicts both time to virological suppression and duration of post-treatment virological control in patients treated with temporary early ART Pasternak, A.
2 S2 p. 2
 artikel
45 OA3-3 Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle can prevent the selection of resistance Nijhuis, M.
2 S2 p. 4-5
 artikel
46 OA2-4 Enhancing HIV-1 virion tethering by BST2/tetherin sensitizes productively and latently infected T cells to ADCC mediated by broadly neutralizing anti-HIV antibodies Pham, T.N.Q.
2 S2 p. 3
 artikel
47 OA1-2 Ethical and social implications of proposed HIV cure research: stakeholder perspectives from South Africa Moodley, K.
2 S2 p. 1
 artikel
48 OA1-3 Factors affecting participation in HIV cure-related research in the United States: implications for effective and ethical implementation Dubé, K.
2 S2 p. 1-2
 artikel
49 OA2-1 Frequent and ‘burst-like’ reactivation from latency in SIVmac239M infected macaques Pinkevych, M.
2 S2 p. 2
 artikel
50 OA4-1 Heterodimeric IL-15 induces effector cell activation and trafficking to the Germinal Centers of SIV infected Macaques Pavlakis, G.N.
2 S2 p. 6
 artikel
51 OA4-2 HIV persists in colon and blood CCR6+CD4+ T cells during ART Gosselin, A.
2 S2 p. 6-7
 artikel
52 OA4-4 Latency reversing agents induce HIV-1 protein expression in latently infected cells for cytotoxic T-lymphocyte antiviral recognition and killing Ruiz, A.
2 S2 p. 7
 artikel
53 OA3-5 LB Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals initiating ART during acute HIV infection Kroon, E.
2 S2 p. 5-6
 artikel
54 OA3-4 LB Elimination of HIV-1 latently infected cells by PKC agonist gnidimacrin alone and in combination with a histone deacetylase inhibitor Huang, L.
2 S2 p. 5
 artikel
55 OA2-5 LB No evidence of ongoing replication in tissue compartments during combination antiretroviral therapy Bozzi, G.
2 S2 p. 3
 artikel
56 OA4-5 LB SIV persistence in ART-treated infant rhesus macaques Mavigner, M.
2 S2 p. 7
 artikel
57 OA4-3 PD-1 blockade combined with ART improves SIV-specific CD8 T cell function and enhances control of pathogenic SIV after ART interruption Mylvaganam, G.H.
2 S2 p. 7
 artikel
58 OA1-1 Unanticipated participant benefits in HIV cure clinical research: a qualitative analysis Gilbertson, A.
2 S2 p. 1
 artikel
59 53 Perceptions of HIV remission (“cure”) trials and trial intentions among potential participants treated in acute HIV infection Peay, H.
2 S2 p. 28
 artikel
60 12 Persistence of HIV DNA in seminal plasma fraction after ART among men who have sex with men and transgender women in the Thailand test & treat cohort Chuang, E.
2 S2 p. 12-13
 artikel
61 4 Post-treatment control or treated controllers? The impact of ART on time to viral rebound in recent seroconverters Martin, G.E.
2 S2 p. 9
 artikel
62 7 Presence of HIV-1C broadly neutralizing antibodies in pregnancy and at delivery Mduluza, T.
2 S2 p. 10
 artikel
63 19 Quantification and correlates of the replication competent HIV-1 latent viral reservoir in a virally suppressed Ugandan population Prodger, J.L.
2 S2 p. 15
 artikel
64 43 siRNA based TLR7/8 activation, MHC class I recycling from endosome and cross presentation of HIV-1 antigen for elevated CD8+ response: an approach for intracellular vaccine Adhikari, A.
2 S2 p. 24-25
 artikel
65 20 Sirtuin1 inhibitor nicotinamide disrupts HIV-1 latency Samer, S.
2 S2 p. 15-16
 artikel
66 38 Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal De Crignis, E.
2 S2 p. 22
 artikel
67 31 Systematic review of the current literature on structured treatment interruptions in HIV-infected patients receiving antiretroviral therapy – implications for future HIV cure trials Stecher, M.
2 S2 p. 19
 artikel
68 25 Targeting HSF1-mediated stress response can enhance Hsp90 inhibitor-induced suppression of HIV-1 reactivation from latency Kabakov, A.
2 S2 p. 17
 artikel
69 24 Thalidomide reverses latency of HIV-1 provirus Samer, S.
2 S2 p. 17
 artikel
70 10 The interferon-inducible restriction factor TRIM22 contributes to HIV-1 latency Turrini, F.
2 S2 p. 11
 artikel
71 27 Therapeutic immune recovery prevents emergence of CXCR4-tropic HIV-1 Bader, J.
2 S2 p. 18
 artikel
72 35 Therapy with the immunomodulatory agent pomalidomide does not lead to changes in HIV-1 viral populations in vivo Watters, S.A.
2 S2 p. 21
 artikel
73 21 T regulatory cell depletion in controller macaques reactivates SIV and boosts CTLs He, T.
2 S2 p. 16
 artikel
74 23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal Mota, T.M.
2 S2 p. 16-17
 artikel
75 49 Using ddPCR to assess persistence of HIV DNA reservoirs in perinatally infected infants treated with cART before or after 12 months of age Soni, P.
2 S2 p. 26-27
 artikel
76 41 Vitamin D level in cART treated patients is critical for HIV reservoir size Chéret, A.
2 S2 p. 24
 artikel
77 44 Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya Nyaoke, B.A.
2 S2 p. 25
 artikel
                             77 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland